Accounts Receivable and Notes Receivable

3 Months Ended

Mar. 31, 2022

Receivables [Abstract]

Accounts Receivable and Notes Receivable

Accounts Receivable and Notes ReceivableThe Company’s accounts receivable consists primarily of amounts due from third-party payors and patients. See Note 2 for a summary of the Company’s policies relating to accounts receivable.

Accounts Receivable as of March 31, 2022 and December 31, 2021 consist of the following:

(in thousands)	March 31, 2022		December 31, 2021
Oral drug accounts receivable	$	2,535	$	2,097
Capitated accounts receivable	721		665
FFS accounts receivable	15,518		12,530
Clinical trials accounts receivable	1,849		1,823
Other trade receivables	3,890		2,892
Total	$	24,513	$	20,007

During the three months ended March 31, 2022 and 2021 bad debt related to direct write-offs totaled $177 and $0, respectively. Bad debt write-offs were a result of accounts receivable on completed contracts that were deemed uncollectible during the period due to delayed collection efforts. In the three months ended March 31, 2022 and 2021, the Company had bad debt recoveries of $23 and $0, respectively